Results from the Phase II AZUR-1 trial showed that 100% of participants treated with Jemperli for mismatch repair-deficient locally advanced rectal cancer achieved a complete clinical response.
Data presented at ASCO show improved complete response rates with Gemperli as first-line treatment for locally advanced rectal cancer in patients with mismatch repair deficiency
Leave a comment
